Major Setback for Novo Nordisk! Losing Billions Over Drug Trial Failures
Novo Nordisk, the Danish pharmaceutical giant, faced an impressive market decline of nearly 20% following disappointing trial results for its latest obesity drug, CagriSema. This significant drop marks one of…